Open AccessA cocktail of betulinic acid, parthenolide, honokiol and ginsenoside Rh2 in liposome systems for lung cancer treatment
Author(s) -
Xin Jin,
Qing Yang,
Ning Cai,
Zhenhai Zhang
Publication year - 2020
Publication title -
nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.947
H-Index - 109
eISSN - 1748-6963
pISSN - 1743-5889
DOI - 10.2217/nnm-2018-0479
Subject(s) - parthenolide , betulinic acid , honokiol , liposome , pharmacology , lung cancer , medicine , triptolide , in vivo , natural product , chemistry , traditional medicine , oncology , biochemistry , biology , apoptosis , microbiology and biotechnology , genetics
Aim: Lung cancer has a very high incidence rate, and thus, there is an urgent need for novel and effective therapies. Materials & methods: In this study, we proposed a potential treatment option by combining four natural products in liposome systems. Results: In vitro studies indicated that the combination of betulinic acid, parthenolide, honokiol and ginsenoside Rh2 exhibited a synergistic action. When these four natural products were loaded into liposome systems, we observed an increased effect. The relative action was also observed in vivo. The cisplatin group presented obvious kidney damage, whereas both cocktail therapy and cocktail liposome therapy were safer. Conclusion: Therefore, we propose cocktail liposome systems may provide a more efficient and safer treatment for lung cancer.